MAY 24, 2019 10:14 PM PDT

First Anticoagulant Approved for Pediatric Patients to Treat Potentially Life-Threatening Blood Clots

WRITTEN BY: Nouran Amin

The approval of the drug Fragmin, an anti-coagulant subcutaneous use, will seek to reduce the recurrence of symptomatic venous thromboembolism (VTE) in pediatric patients—which can include deep vein thrombosis and pulmonary embolism that may lead to death.

VTE can develop as a secondary complication from a broad spectrum of underlying clinical conditions such as a venous catheter, cancer, infection, congenital heart disease, and trauma or surgery and is associated with an increased risk of in-hospital mortality.

Although Fragmin was approved in 1994 for adult patients, it will be the first drug for the pediatric treatment for VTE.

Learn more about VTE:

“Most children who have VTE are fighting a serious underlying primary illness such as cancer or congenital heart disease. Not only are they fighting a serious illness, having a condition like VTE can then lead to significant complications and even death,” said Richard Pazdur, M.D., director of the FDA’s Oncology Center of Excellence and acting director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research.

Some issues with Fragmin may include bleeding and hemorrhage amongst other possible complications.

“Prior to this approval, there had been no FDA-approved therapies to treat VTE in pediatric patients. Given the unmet need, we granted the Fragmin application priority review and today we are approving it as the first anticoagulant (blood thinner) indicated for pediatric patients. We remain committed to advancing treatments for children with unmet medical needs.”

Source: Science Daily

 

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
JUN 18, 2019
Drug Discovery
JUN 18, 2019
Nicotine on Human Embryonic Development
Researchers report in a study published in the journal Stem Cell Reports, that nicotine exerted adverse effects on human embryonic development at the cellu...
JUN 18, 2019
Health & Medicine
JUN 18, 2019
Can a Low-Carb Diet Treat Osteoarthritis?
A pilot study suggests it might. Researchers at the University of Alabama, Birmingham, found that a low-carbohydrate diet was able to reduce pain intensity...
JUN 18, 2019
Drug Discovery
JUN 18, 2019
Type 2 Diabetic Drug Reverses Heart Failure
In a study published in the Journal of American Cardiology, a drug used for the treatment of diabetes—empagliflozin—was shown to improve the he...
JUN 18, 2019
Drug Discovery
JUN 18, 2019
How a Cancer Drug Inhibits DNA Repair in Cancer Cells
In a study published in the journal Science Translational Medicine, combing a certain cancer drug with other agents could potentially deliver a lethal blow...
JUN 18, 2019
Cardiology
JUN 18, 2019
Hallucinogens As Mental Health Treatments
In a time when once-demonized substances are being recognized for their potential health benefits, what role should psychedelics play in our treatment of m...
JUN 18, 2019
Drug Discovery
JUN 18, 2019
Sustainable Production of Opiate Antidotes
According to the National Center for Health Statistics, an estimated 130 Americans die every day from an opioid overdose. The skyrocketing of opiate overdo...
Loading Comments...